Lilly Oncology International

How do clinicians choose what comes next in #CLL care? Dr. @MosqueraOrgeira breaks down how risk profiles, resistance patterns, and preferences guide personalized care decisions.

Dr. @GuiperiniMD discusses how options after BTK inhibitor failure in #MantleCellLymphoma were once limited, but advances in this setting are creating new opportunities. Hear what lies ahead for these patients; watch the full video.

Have you considered a molecular approach to assessing #RiskOfRecurrence? ctDNA detection can be used in the clinic to improve patient prognosis and monitor response to therapy in patients with #EarlyBreastCancer.

Watch Dr. Pfitzner-Dempfle explain how TTNT provides real-world insight into disease control, adherence, and tolerability in #HematologicalMalignancy, supporting shared decisions and more personalized care.

Time to next treatment can reveal how well #CLL is being managed. In what ways does tracking TTNT influence your therapeutic planning or guide expectations in discussions with patients¹?

Did you know that original nodal status and tumor diameter are remarkably strong determinants of #RiskOfRecurrence among patients with HR+ #EarlyBreastCancer. Follow us for more Breast Cancer Insights.

Watch Dr. Scarfò describe how detecting resistance mutations and adverse genetics can guide tailored #CLL care,¹ and the need for further effective care to improve patient outcomes.²

In HR+/HER2– #EarlyBreastCancer, assessing #RiskOfRecurrence requires more than one approach. Dr @Rodrosb explains how clinical features, genomic tools, biomarkers, and multidisciplinary care can refine risk assessment and guide management.

The Binet staging system is a key tool in #CLL, using simple physical findings such as enlarged lymph nodes or detectable spleen/liver involvement to classify disease extent. This helps clinicians estimate risk and guide care.

Watch Dr. Marcelo Pitombeira de Lacerda describe how clear, compassionate communication and shared decision-making can improve care and empower patients with #HematologicalMalignancy, aligning with Lilly’s commitment to patient-centered care.

More than 40% of patients with #Lymphoma do not feel well informed about their healthcare, according to a Lymphoma Coalition report. Read the full report here: e.lilly/4bPVWxS

Management of HR+, HER2− #EarlyBreastCancer continues to evolve, but long-term recurrence remains a challenge for many patients – even after 20 years.¹,² Recognizing those at risk can improve outcomes.¹,² Follow for more.

Cancer guidelines recommend that clinicians should provide diagnostic and prognostic information that is tailored to patient needs and provides reassurance without misleading the patient, including those with #HematologicalMalignancy.¹

Patients with #HematologicalMalignancy have different information preferences. In a multicenter study of 216 patients, most preferred multiple ways to hear about treatment success, and 88% favored percentages. Aligning communication with preferences supports better decisions.

Even patients with a low nodal burden may face a high #RiskOfRecurrence in HR+/HER2- #EarlyBreastCancer. Watch Professor Marc Thill provide his expert perspective on why even a low nodal burden influences long-term recurrence risk and survival.

In 2025, voices from across the global community came together to exchange ideas, share knowledge, and help move care forward in #CLL, #MCL, and #BreastCancer. Thank you to everyone who engaged, contributed, and helped shape the conversation. We look ahead to 2026!

Beyond diagnosis, #CLL patients face daily fatigue impacting quality of life. Regular fatigue assessment & multidisciplinary care can make a meaningful difference. What approaches help empower your patients to live better despite these challenges?

Generative AI is reshaping how we approach medical documentation, education, and research. Dr. @MosqueraOrgeira explains its emerging applications—alongside the critical need for clinical oversight and ethical integration.

Effective management of HR-positive, HER2-negative Breast Cancer in younger women requires special consideration to help improve outcomes, as this group is more likely to experience late recurrence. What factors lead to delayed detection in younger women at risk?

Reflecting on an incredible #ASH25 in Orlando! The Lilly team described in one word what being part of this global #Hematology congress meant to them. Proud to stand united in advancing science and shaping the future of patient care.